市场调查报告书
商品编码
1370463
生命科学市场中的人工智慧:2023-2028 年全球产业趋势、份额、规模、成长、机会和预测Artificial Intelligence In Life Sciences Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球生命科学人工智慧市场规模达到19亿美元。展望未来,IMARC集团预计到2028年市场规模将达到82亿美元,2023-2028年复合年增长率(CAGR)为25.7%。
人工智慧 (AI) 是一种高度数据驱动的技术,用于生命科学中收集、分析和管理患者资料。它通常用于医学诊断、临床试验、药物发现、生物技术、患者监测、精准医疗和个人化医疗。它也用于生产个人化治疗、配製药物、诊断疾病以及引入疗法和机器人手术。生命科学中的人工智慧有助于重塑商业模式,增强认知分子研究和工作流程,并简化生物製药製造。它还可以节省宝贵的时间、提高效率、降低整体成本、增强客户体验并消除人为错误。
目前,癌症等复杂疾病盛行率的上升是推动市场成长的关键因素之一。生命科学领域的人工智慧被广泛应用于为患者设计具有特定分子标靶的有效药物组合。此外,全球临床试验数量的不断增加导致公共领域可用的大量资料激增。这反过来又为市场成长创造了有利可图的机会。除此之外,引入可靠且先进的云端运算基础设施可以轻鬆管理、共享和储存资料,并帮助根据要求改善组织运营,这为市场提供了推动力。此外,分析和解释大量结构化和非结构化临床资料的需求不断增长,这是另一个成长诱导因素。除此之外,广泛的研发(R&D)活动、机器人手术利用率的提高以及政府为推进医疗基础设施而实施的各种倡议预计将推动市场在预测期内实现成长。
The global artificial intelligence in life sciences market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 25.7% during 2023-2028..
Artificial intelligence (AI) is a highly data-driven technology that is used in life sciences to collect, analyze, and manage data of patients. It is commonly employed for medical diagnosis, clinical trials, drug discovery, biotechnology, patient monitoring, precision, and personalized medicine. It is also utilized for producing personalized treatments, formulating drugs, diagnosing diseases, and introducing therapies and robotic surgeries. AI in life sciences helps reshape business models, enhance cognitive molecule research and workflow, and streamline biopharmaceutical manufacturing. It also saves valuable time, improves efficiency, reduces overall costs, enhances customer experience, and eliminates human error.
At present, the rising prevalence of complex diseases, such as cancer, represents one of the key factors impelling the market growth. AI in life sciences is widely used to design effective drug combinations with specific molecular targets for patients. Additionally, the growing number of clinical trials across the globe is resulting in the surging production of colossal amounts of data available in the public domain. This, in turn, is creating lucrative opportunities for the market growth. Apart from this, the introduction of reliable and advanced cloud computing infrastructure that can easily manage, share, and store data and help improve organizational operations as per the requirements are providing a boost to the market. Moreover, the growing need to analyze and interpret large volumes of structured and unstructured clinical data is acting as another growth-inducing factor. Apart from this, extensive research and development (R&D) activities, rising utilization of robotics surgeries, and the implementation of various government initiatives to advance the medical infrastructure are anticipated to drive the market toward growth in the forecasted period.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial intelligence in life sciences market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on offering, deployment and application.
Software
Hardware
Services
On-premises
Cloud-based
Drug Discovery
Medical Diagnosis
Biotechnology
Clinical Trails
Precision and Personalized Medicine
Patient Monitoring
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AiCure LLC, Apixio Inc. (Centene Corporation), Atomwise Inc, Enlitic Inc., International Business Machines Corporation, Insilico Medicine Inc., Nuance Communications Inc., NuMedii Inc., Sensely Inc. and Sophia Genetics SA.
Table 7 Global: Artificial Intelligence In Life Sciences Market: Key Players